Effect of an intensive 3-day social cognitive treatment (can do treatment) on control self-efficacy in patients with relapsing remitting multiple sclerosis and low disability: A single-centre randomized controlled trial
| Autor: | Job Cornelissen, Michel Bos, Maarten van Droffelaar, Leo H. Visser, Ghislaine A. P. G. van Mastrigt, Joyce Valkenburg-Vissers, Marco Heerings, Rob Ruimschotel, Peter Joseph Jongen, Lotte Duyverman, Rogier Donders, Astrid Hussaarts |
|---|---|
| Přispěvatelé: | Health Services Research, RS: CAPHRI - R2 - Creating Value-Based Health Care |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Social Cognition
Male AUTONOMY Multiple Sclerosis Relapsing-Remitting/therapy medicine.medical_treatment Health Care Providers Emotions Social Sciences Nurses Hospital Anxiety and Depression Scale Geographical locations law.invention Disability Evaluation Randomized controlled trial law QUALITY-OF-LIFE Clinical endpoint Medicine and Health Sciences Medicine Psychology ANXIETY Medical Personnel Netherlands Multidisciplinary Depression Neurodegenerative Diseases Self Efficacy Intention to Treat Analysis Cognitive behavioral therapy Europe Professions Neurology Research Design Observational Studies Anxiety Female medicine.symptom INTERVENTION Research Article Adult medicine.medical_specialty Multiple Sclerosis Patients Social Psychology Science Immunology PARTICIPATION Research and Analysis Methods VALIDATION Autoimmune Diseases Multiple Sclerosis Relapsing-Remitting PEOPLE Mental Health and Psychiatry Humans European Union Relapsing-Remitting/therapy Expanded Disability Status Scale Intention-to-treat analysis Cognitive Behavioral Therapy business.industry Mood Disorders Cognitive Psychology Biology and Life Sciences Demyelinating Disorders Health Care PHYSICAL-ACTIVITY Case-Control Studies People and Places Physical therapy Cognitive Science Observational study Clinical Immunology Population Groupings Clinical Medicine business Neuroscience Follow-Up Studies |
| Zdroj: | PLoS ONE, 14(10):0223482. PUBLIC LIBRARY SCIENCE PLoS ONE PLOS ONE, 14(10):e0223482. Public Library of Science PLoS ONE, Vol 14, Iss 10, p e0223482 (2019) |
| ISSN: | 1932-6203 |
| Popis: | In patients with chronic disorders, control self-efficacy is the confidence with managing symptoms and coping with the demands of illness. Can do treatment (CDT) is an intensive, 3-day, social cognitive theory-based, multidisciplinary treatment that focuses on identification of stressors, goal setting, exploration of boundaries, and establishment of new boundaries. An uncontrolled study showed that patients with relapsing remitting multiple sclerosis (RRMS) and low-disability had improved control self-efficacy six months after CDT. Hence, in a 6-month, single-centre, randomized (1:1), unmasked, controlled trial in RRMS patients with Expanded Disability Status Scale (EDSS) score ≤4.0, we compared CDT with no intervention and the option to receive CDT after completion of study participation. Follow-up assessments were at one, three and six months. Primary endpoint was control self-efficacy (Multiple Sclerosis Self-Efficacy Scale Control [MSSES-C] (minimum 90, maximum 900) at six months. Secondary endpoints were functional self-efficacy (MSSES-F), participation and autonomy (Impact on Participation and Autonomy questionnaire [IPA]), health-related quality of life (MS Quality of Life-54 Items questionnaire [MSQoL-54]), anxiety, depression (Hospital Anxiety and Depression Scale [HADS]) and coping skills (Utrecht Coping List [UCL]) at six months. Tertiary endpoint was care-related strain on support partners (Caregiver Strain Index) at six months. Of the 158 patients that were included, 79 were assigned to CDT and 79 to the control group. Two CDT patients discontinued treatment prematurely. Sixty-one (77%) control patients chose to receive CDT after study participation. Intention-to-treat ANCOVA analyses were performed with follow-up values as dependent, and condition, baseline values, disease duration and gender as independent variables. The mean (standard deviation [SD]) MSSES-C score in the CDT group vs. control group at baseline was 468 (162) vs. 477 (136), and at six months 578 (166) vs. 540 (135) (p = 0.100). Secondary and tertiary endpoints did not differ between groups, except for the UCL palliative reaction score being slightly higher in the CDT group (p = 0.039). On post hoc analyses the MSSES-C score at one and three months was higher in the CDT vs. control group: 597 (114) vs. 491 (131) (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|